Charles River Laboratories International, Inc.
CRL
Clasificación en acciones
#1445
Charles River Laboratories International, Inc. operates as a contract research... Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Precio por acción
$317.20
Última sincronización: 2026-10-20
Capitalización bursátil
$15.28B
Cambio (1 día)
6.02%
Cambio (1 año)
68.49%
País
US
Comercio Charles River Laboratories International, Inc. (CRL)
Categoría
Healthcare
Ratio P/E de Charles River Laboratories International, Inc. (CRL)
Ratio P/E al October 2026 TTM: -62.40
Según los últimos informes financieros y el precio de las acciones de Charles River Laboratories International, Inc., el P/E actual (TTM) de la empresa es -62.40. Al final de 2023, la empresa tenía un P/E de 25.52.
Historial del ratio P/E de Charles River Laboratories International, Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | -62.40 | -106.77% |
| 2024 | 921.12 | 3,510.09% |
| 2023 | 25.52 | 12.05% |
| 2022 | 22.77 | -52.05% |
| 2021 | 47.49 | 38.72% |
| 2020 | 34.24 | 16.54% |
| 2019 | 29.38 | 24.15% |
| 2018 | 23.66 | -43.83% |
| 2017 | 42.13 | 82.02% |
| 2016 | 23.14 | -7.19% |
| 2015 | 24.94 | 5.40% |
| 2014 | 23.66 | -4.44% |
| 2013 | 24.76 | 36.33% |
| 2012 | 18.16 | 43.26% |
| 2011 | 12.68 | -291.10% |
| 2010 | -6.63 | -135.24% |
| 2009 | 18.83 | -683.66% |
| 2008 | -3.23 | -111.25% |
| 2007 | 28.67 | -153.70% |
| 2006 | -53.40 | -357.08% |
| 2005 | 20.77 | -19.23% |
| 2004 | 25.71 | 34.65% |
| 2003 | 19.10 | -44.07% |
| 2002 | 34.14 | -13.64% |
| 2001 | 39.53 | -157.77% |
| 2000 | -68.44 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 36.15 | -157.94% |
US
|
|
| 39.77 | -163.74% |
US
|
|
| -290.26 | 365.18% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -154.79% |
US
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.